Suscripción a Biblioteca: Guest
Critical Reviews™ in Oncogenesis

Publicado 4 números por año

ISSN Imprimir: 0893-9675

ISSN En Línea: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

The IAP Protein Family, SMAC Mimetics and Cancer Treatment

Volumen 21, Edición 3-4, 2016, pp. 185-202
DOI: 10.1615/CritRevOncog.2016017032
Get accessGet access

SINOPSIS

Since the acquired resistance of cells to apoptosis is one of the major hallmarks of cancer, the endogenous inhibitors of apoptosis can be regarded as promising targets in the design of anticancer therapeutics. In addition to their antiapoptotic activity, inhibitor of apoptosis proteins (IAPs) are able to regulate numerous other cell functions, including proliferation, differentiation, and migration, as well as proinflammatory and immune responses. Study of the IAP family as target molecules in targeted therapies has recently focused on SMAC mimetics as synthetic IAP antagonists that have been under development as promising therapeutics. To overview the background of IAP proteins and to focus on the development of SMAC mimetics, the present review first looks at the mechanisms of IAP proteins' antiapoptotic activities and those for controlling those activities; then the SMAC mimetics, including birinapant, LCL161, and DEBIO1143/AT-406, and their clinical trials are introduced. To further clarify the processes to exert the efficacies of SMAC mimetics, it is necessary to determine therapeutic biomarkers that predict and assess them, which may include caspases and factors in the TNFα pathway.

CITADO POR
  1. Huang Xianbo, Xiao Feng, Li Yuan, Qian Wenbin, Ding Wei, Ye Xiujin, Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia, Journal of Experimental & Clinical Cancer Research, 37, 1, 2018. Crossref

  2. Thibault Benoît, Genre Ludivine, Le Naour Augustin, Broca Clothilde, Mery Eliane, Vuagniaux Grégoire, Delord Jean Pierre, Wiedemann Norbert, Couderc Bettina, DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death, Scientific Reports, 8, 1, 2018. Crossref

  3. Pereira Joana M., Peixoto Vanessa, Teixeira Alexandra, Sousa Diana, Barros Lillian, Ferreira Isabel C.F.R., Vasconcelos M. Helena, Achillea millefolium L. hydroethanolic extract inhibits growth of human tumor cell lines by interfering with cell cycle and inducing apoptosis, Food and Chemical Toxicology, 118, 2018. Crossref

  4. Dubois Fatéméh, Keller Maureen, Hoflack Julien, Maille Elodie, Antoine Martine, Westeel Virginie, Bergot Emmanuel, Quoix Elisabeth, Lavolé Armelle, Bigay-Game Laurence, Pujol Jean-Louis, Langlais Alexandra, Morin Franck, Zalcman Gérard, Levallet Guénaëlle, Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial, Cancers, 11, 12, 2019. Crossref

  5. Bobardt Michael, Kuo Joseph, Chatterji Udayan, Chanda Sumit, Little Susan J., Wiedemann Norbert, Vuagniaux Gregoire, Gallay Philippe A., Sluis-Cremer Nicolas, The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate, PLOS ONE, 14, 2, 2019. Crossref

  6. Kuo Yung-Chih, Rajesh Rajendiran, Biomaterial-based drug delivery systems used to improve chemotherapeutic activity of pharmaceuticals and to target inhibitors of apoptosis proteins, Journal of the Taiwan Institute of Chemical Engineers, 111, 2020. Crossref

  7. Duan Xiaohui, Yang Jianhui, Jiang Bo, Duan Wenbin, Wei Rongguang, Zhang Hui, Mao Xianhai, Knockdown of PSMC2 contributes to suppression of cholangiocarcinoma development by regulating CDK1, Aging, 13, 17, 2021. Crossref

  8. Zhang Xiaotong, Zhang Jiarun, Zhang Hao, Liu Yang, Yin Lei, Liu Xi, Li Xuejie, Yu Xiuyue, Yao Jinlong, Zhang Zhe, Kong Chuize, Exploring the five different genes associated with PKCα in bladder cancer based on gene expression microarray, Journal of Cellular and Molecular Medicine, 25, 3, 2021. Crossref

  9. Vellanki Sri HariKrishna, Cruz Rodrigo G.B., Jahns Hanne, Hudson Lance, Sette Giovanni, Eramo Adriana, Hopkins Ann M., Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth, Cancer Letters, 440-441, 2019. Crossref

  10. Townsend Paul A., Kozhevnikova Maria V., Cexus Olivier N. F., Zamyatnin Andrey A., Soond Surinder M., BH3-mimetics: recent developments in cancer therapy, Journal of Experimental & Clinical Cancer Research, 40, 1, 2021. Crossref

  11. Tewary Poonam, Brooks Alan D., Xu Ya-Ming, Wijeratne E.M. Kithsiri, Babyak Ashley L., Back Timothy C., Chari Raj, Evans Christine N., Henrich Curtis J., Meyer Thomas J., Edmondson Elijah F., de Aquino Maria T. Prudente, Kanagasabai Thanigaivelan, Shanker Anil, Gunatilaka A.A. Leslie, Sayers Thomas J., Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins, Cancer Research, 81, 12, 2021. Crossref

  12. Jin Gongshen, Wang Kangwei, Liu Yonghong, Liu Xianhu, Zhang Xiaojing, Zhang Hao, Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug- Resistant Cells, Anti-Cancer Agents in Medicinal Chemistry, 20, 6, 2020. Crossref

  13. Arnett Eusondia, Schlesinger Larry S., Live and let die: TB control by enhancing apoptosis, Immunity, 54, 8, 2021. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain